PatientsVille.com LogoPatientsVille.com

Ocular Surface Disease | Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma

Ocular Surface Disease research study

What is the primary objective of this study?

To study effect of hydroxypropylmethylcellulose 0.3% and sodium hyaluronate 0.18% in the treatment of ocular surface disease in glaucoma patients.

Who is eligible to participate?

Inclusion Criteria: - OSDI > or equal 20 and eye lid inflammation , meibomian gland inflammation,conjunctival injection,follicle at tarsus , positive corneal staining , tear break up time less than 8 seconds , tear volume less than 5.5 mm. Exclusion Criteria: - Age below 18 yo - Active infectious corneal disease - Post penetrating keratoplasty or glaucoma drainage device - Known allergy to medication - Lactation , Pregnant

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Ocular Surface Disease

Glaucoma

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:hydroxypropylmethylcelluloseTearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month

Drug:sodium hyaluronateQID to every 2 hous, 1-2 drops per each time, duration 1 month

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

TearA

TearB

Study Status

Unknown status

Start Date: January 2011

Completed Date: February 2012

Phase: N/A

Type: Interventional

Design:

Primary Outcome: Ocular surface index score

Secondary Outcome: Eye lid inflammation, corneal staining score, tear break up time and tear volume

Study sponsors, principal investigator, and references

Principal Investigator: AssocProf Pinnita Tanthuvanit, MD

Lead Sponsor: Mahidol University

Collaborator:

More information:https://clinicaltrials.gov/show/NCT01284439

Discuss Genteal